pharma · Advanced Solid Tumor · RNAZ
Transcode Therapeutics
Transcenta Therapeutics is a pharma organization headquartered in Princeton, USA. It trades on NYSE under ticker RNAZ. Primary therapeutic focus areas include Advanced Solid Tumor. NovaPharmaNews links 2 clinical program
Princeton, USA HQ
93 Employees
Public company Type
RNAZ · NYSE Ticker
Company details
- Status
- Public
- HQ
- Princeton, USA
- Employees
- 93
- Programs
- 2
- Drugs
- 0
- Patents
- 0
TTX-MC138-NODAGA-Cu64
Phase 1 · small molecule · Advanced Solid Tumor
TTX-MC138-NODAGA-Cu64 for Advanced Solid Tumor is a Phase 1 program (small_molecule) at Transcode Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code TTX-MC138-NODAGA-Cu64-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Transcode Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Advanced Solid Tumor
- Status
- completed
- Trials
- 1